Brokerage firm PiperJaffray Downgrades its rating on Alcobra Ltd(NASDAQ:ADHD). The shares have been rated Neutral. Previously, the analysts had a Overweight rating on the shares. The rating by PiperJaffray was issued on Sep 30, 2016.
In a different note, On Sep 29, 2016, Cantor Fitzgerald said it Downgrades its rating on Alcobra Ltd. The shares have been rated ‘Hold’ by the firm. On Sep 29, 2016, Oppenheimer said it Downgrades its rating on Alcobra Ltd. The shares have been rated ‘Perform’ by the firm. On Sep 12, 2016, WBB Securities said it Downgrades its rating on Alcobra Ltd. The shares have been rated ‘Sell’ by the firm. Barclays said it Initiates Coverage on Alcobra Ltd, according to a research note issued on Aug 1, 2016. The shares have been rated ‘Equal-weight’ by the firm.
Alcobra Ltd (ADHD) made into the market gainers list on Tuesdays trading session with the shares advancing 1.92% or 0.05 points. Due to strong positive momentum, the stock ended at $2.65, which is also near the day’s high of $2.72. The stock began the session at $2.64 and the volume stood at 4,21,029 shares. The 52-week high of the shares is $8.78 and the 52 week low is $1.95. The company has a current market capitalization of $73 M and it has 2,75,60,920 shares in outstanding.
Alcobra Ltd(ADHD) last announced its earnings results on Aug 30, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.21. Analysts had estimated an EPS of $-0.22.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug MG01CI to treat Attention Deficit Hyperactivity Disorder (ADHD) a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs higher divorce rates lower levels of socioeconomic attainment lower academic achievement unemployment and work place deficits increased risks for motor vehicle accidents greater likelihood of additional psychiatric disorders increased criminal activity and incarceration and higher rates of substance use and abuse. MG01CI product has completed phase two studies.